Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group
BURLINGTON, Mass., June 18, 2014 /PRNewswire/ -- Decision Resources Group finds that China's market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated population, following the introduction of novel HCV therapies. Nearly a third of patients diagnosed with HCV do not receive the current standard of treatment-the combination of pegylated-interferon-alpha (peg-IFN-alpha) and ribavirin-because they have not responded to this regimen in the past. The arrival of IFN-free regimens will bring patients who have not responded to currently available drugs back into treatment, thereby significantly increasing the drug-treated population.
Other key findings from the Special Report Patient Flow in Hepatitis C Virus: Changing Treatment Dynamics in China include:
Facts about the Chinese HCV market:
Comments from Decision Resources Group Analyst Youling Guo, Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.
All content © Copyright 2000 - 2014 WorldNow and KIII. All Rights Reserved.
Users of this site agree to the Terms of Service, Privacy Notice/Your California Privacy Rights, and Ad Choices.